Konjac glucomannan (Viscosity≥15000mPa.s)

Konjac glucomannan (Viscosity≥15000 mPa·s) (squid surimi enriched with 30% glucomannan; administered orally; once daily; for 7 weeks) controls hyperglycemia and increases adiponectin levels in adipose tissue of Zucker fa/fa rats, exhibiting anti-hypertrophic and insulin-sensitizing adipocytokine effects^[1].
Konjac glucomannan (Viscosity≥15000 mPa·s) (2.5-5% liquid konjac powder; p.o.; daily; 80 days) prevents obesity in male C57BL/6J mice by reducing abdominal and hepatic lipid accumulation and regulating obesity-related serum indicators^[1].
Konjac glucomannan (Viscosity≥15000 mPa·s) (administered orally; daily dosing; for 45 consecutive days) significantly improves anti-obesity activity in obese male Sprague-Dawley rats^[1].
Konjac glucomannan (Viscosity≥15000 mPa·s) (p.o.; daily; 8 or 9 weeks) induces anti-inflammatory immune responses in atopic dermatitis NC/Nga mice^[1].
Konjac glucomannan (Viscosity≥15000 mPa·s) coats porous hydroxyapatite scaffolds, and the modified scaffolds achieve efficient bone repair in Rattus norvegicus by matching the scaffold degradation rate to new bone growth, as well as promoting osteogenic differentiation and angiogenesis^[3].
Konjac glucomannan hydrolysate (Viscosity≥15000 mPa·s) (administered orally; daily dosing; for 4 consecutive weeks) inhibits IgE production in ovalbumin-immunized Balb/c mice, making it a practical dietary supplement for the prevention of atopic diseases^[1].
Konjac glucomannan (Viscosity≥15000 mPa·s) (administered orally; daily; starting 2 weeks before colitis induction and continuing throughout the study period) alleviates Oxazolone (HY-126360)-induced colitis in C57BL/6 mice by promoting Th1-polarized immune responses^[1].